P C Egbe

Learn More
Amperozide given subcutaneously (0.25 mg/kg) depressed amphetamine-induced locomotor activity by 40%. In the absence of amphetamine (1.5 mg/kg), this dose of amperozide had no effect on locomotor activity during the 60 min test period. Amperozide (0.1-1 mg/kg) dose-dependently decreased the locomotor activity of mice as measured in motron boxes. Only doses(More)
Amperozide, a new putatively antipsychotic compound, has been evaluated for its effect on conditioned avoidance response and food-reinforced lever-pressing. Given alone, amperozide was almost equipotent to clozapine, but less potent than haloperidol in both test models. It was found that there was a statistically significant synergism, in these two models,(More)
Physostigmine-induced hyperactivity in rats was attenuated by reserpine 5 mg/kg) and haloperidol (0.025 mg/kg). Pretreatment with (bis-4-methyl-1-homopiperizinyl-his-carbonyl) disulphide (FLA-63) (2.5 mg/kg) resulted in physostigmine producing a biphasic effect on rats' locomotion while pretreatment with p-chloro-phenylalanine (pCPA) (300 mg/kg) did not(More)
Intraperitoneal administration of physostigmine (0.025 to 0.18 mg/kg) to rats resulted in significant increases in motor activity as measured with jiggle platforms. Doses of physostigmine 0.2 mg/kg or more decreased motor activity. The physostigmine-induced hyperactivity was attenuated by atropine (5 mg/kg) given before or after physostigmine (0.05 mg/kg).(More)
  • 1